... the series of studies of the ECOG and US Inter-group known as E1684, E1690, E1694, and the meta-analysis of all trials of IFN-a, which have confirmed adurable and significant impact of this therapy ... 9:32http://www.translational-medicine.com/content/9/1/32Page 7 of 12melanoma and suggest that future studies of other r iskbiomarkers may add to our pro gnostic assessment of patients for adjuvant therapy. On the other hand, theappearance of autoantibodies ... therapy of high-risk patients, and argues that a year of therapy remains the standard of treatment. Multiplevaccine approaches, including the GSK DERMA phaseIII trial, are studied and are currently...